Merck, a prominent science and technology company, has entered into a Memorandum of Understanding (MOU) with ChemLex, an innovation-driven firm based in Singapore. This partnership aims to advance automated chemistry and technological innovation in the fields of life sciences and electronics. The announcement was made on January 20, 2026, highlighting a mutual commitment to revolutionizing research and development (R&D) practices.
The MOU establishes a collaborative framework that seeks to integrate automated experimentation with advanced chemistry workflows. Merck intends to leverage ChemLex’s expertise in AI-driven automated chemical synthesis to enhance the speed, efficiency, and reproducibility of chemical research across its various business sectors. The collaboration is expected to significantly impact early discovery and development workflows.
Exploring Cooperative Opportunities
Under the terms of the MOU, both companies will investigate potential areas of collaboration, including automated synthesis, reaction optimization, high-throughput experimentation, and the integration of chemistry platforms. The initial focus will be on identifying high-impact chemistry programs, aimed at defining pathways for future collaborative projects.
Marc Horn, President of Merck China, emphasized the strategic importance of this partnership, stating, “This strategic partnership with ChemLex integrates AI and automation into our R&D operations, demonstrating Merck’s commitment to embrace digital transformation and accelerate innovation. We look forward to creating greater value for our customers through this collaboration.”
Dr. Sean Lin, Founder and CEO of ChemLex, shared insights into the potential of their technology. He noted, “Our proprietary chemical synthesis platform that operates 24/7 with an AI closed-loop feedback mechanism is redefining the efficiency boundaries of chemical synthesis. The in-depth collaboration with Merck China not only provides us with valuable opportunities to validate and optimize our technology in broader application scenarios but also enables us to explore the future of intelligent chemical synthesis alongside world-class research teams.”
Commitment to Innovation
The signing of this MOU underscores both organizations’ dedication to scalable, data-rich experimental science. It reflects their shared objective of fostering long-term partnerships that drive innovation at the intersection of chemistry and automation. Discussions will continue to evaluate the next steps within the context of the MOU, paving the way for advancements that could reshape the landscape of chemical research.
This strategic collaboration represents a significant step forward not only for Merck and ChemLex but also for the broader scientific community, promising to enhance the capabilities and outcomes of chemical research in the years to come.
